A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Date Added
January 25th, 2022
PRO Number
Pro00117821
Researcher
James Thomas

List of Studies


Keywords
Cholesterol, Pancreas
Summary

Research study looking for participants with have severe hypertriglyceridemia (elevated fat levels in the blood), which may increase the risk for pancreatitis (inflammation of the pancreas). The study is being carried out to see if a new investigational drug called Evinacumab (human IgG4 monoclonal antibody) decreases the risks of future Recurrent Acute Pancreatitis episodes when given the medication every 4 weeks by infusion for 12 months and follow up visits at 1 and 2 months after your last dose. There will also be 2 follow up telephone calls, so that the total duration you are in the study will be approximately 2 years.

Institution
MUSC
Recruitment Contact
Della MacNicholas
843-876-5012
macnichd@musc.edu



-- OR --